Moderna didn’t meet required rules, regulators found.
U.S. Food and Drug Administration (FDA) inspectors uncovered problems at a Moderna plant used to manufacture a substance that is part of the company’s COVID-19 vaccine, according to a newly released document.
Moderna failed to meet multiple requirements, including rules aimed at minimizing the potential for contamination, according to the document.
FDA inspectors performed inspections at the plant in Norwood, Massachusetts from, Sept. 11 to Sept. 21, visiting nine times in total.
They found that equipment used to manufacture the substance was not cleaned properly before usage, that a mock cleaning done for manufacturing did not adequately simulate the actual process, that written alarm procedures were not followed, and that neither the equipment nor the plant were designed in a way that would make contamination less likely.
Inspectors also learned that Moderna used materials beyond their expiration date.
“There are more than two thousand expired items stored in your … warehouse and cold storage at time of inspection,” Unnee Ranjan, the FDA’s lead investigator, wrote in a summary of the inspections.
The Epoch Times obtained the 6-page document, an FDA Form 483, through a Freedom of Information Act request after the FDA’s media office refused to release it.
The FDA under federal law has the power to inspect facilities and deliver a report setting forth any item produced in a facility that seems to “consist in whole or in part of any filthy, putrid, or decomposed substance” or “has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health.”
A Form 483 is a type of agency report containing “observations” that FDA inspectors “deem to be objectionable.” The observations are delivered to help companies comply with federal law and FDA regulations.
The substance in question was used in Moderna’s COVID-19 vaccine, mRNA-1273, the company’s sole product available to the public, according to the form.
Moderna released eight batches of the substance as it violated manufacturing rules, FDA inspectors said.
